Topic: Epilepsy

More than three years into a French investigation of its anti-epilepsy med Depakine, Sanofi will now face charges that could end up in a courtroom.

Five more pharma companies have joined founders BioMarin and Invitae in sponsoring free genetic testing for children who've had an unprovoked seizure.

As Neurelis awaits an FDA decision on its flagship drug, the company has launched its first seizure awareness campaign.

Epidiolex posted sales more than twice what was expected in Q1, but thanks to some "unusual launch dynamics," the numbers could slow.

BioMarin and Invitae are expanding their free genetic testing program for children with seizures with new partners and a wider patient age range.

GW Pharmaceutical is looking to assure doctors that epilepsy treatment Epidiolex is vastly different from off-the-shelf artisan oils at cannabis shops.

The FDA just approved Epidiolex, the cannabis-based drug that GW Pharma has been toiling over for years, to treat two rare and serious forms of epilepsy.

Sunovion is looking for a hero. Epilepsy heroes, that is.

In case anyone thought it was just the U.S. where pharma is accused of hiking prices, the U.K. has been quick to remind everyone it happens across the pond, hitting Pfizer with a £10,000 penalty.